TOBI 2017 speaker David Rabago, MD, along with co-authors from the University of Wisconsin School of Medicine and Public Health recently published a report in the Journal of Alternative and Complementary Medicine documenting the results of patients treated with Prolotherapy for Knee osteoarthritis (OA). Most patients reported a decrease in pain after injections in and around the knee joint. Additionally, many patients reported increased knee function as well.
Rabago told Orthopedics This Week, “Prolotherapy now has strong evidence that it improves symptoms of knee osteoarthritis in randomized control trial [RCT] and meta-analysis studies. Missing from the literature is the patients’ voice regarding outcomes after prolotherapy. Hence the current study. Prolotherapy is a non-surgical therapy supported by RCT and meta-analysis data reporting that Prolotherapy improves knee symptoms and may be disease modifying for osteoarthritis. Prolotherapy improves knee related symptoms and overall knee related quality of life in knee osteoarthritis. Given that prolotherapy safely improves knee symptoms, it is reasonable to treat patients with this safe, conservative therapy prior to total knee arthroplasty as part of routine care for knee osteoarthritis.”
TOBI looks forward to welcoming Rabago to TOBI 2017 in June, where he will speak further about prolotherapy for Knee OA.
See the full study here.
For the latest orthobiologics research and best practices from global field leaders, join us at TOBI 2017:
The Orthobiologic Institute (TOBI)
7th Annual PRP & Regenerative Medicine Symposium with Workshops & Cadaver Labs (TOBI 2017)
June 8-10, 2017
Wynn, Las Vegas, NV